Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
SOTYKTU: selected primary-label renal guidance and limits
Product / population
Adult oral SOTYKTU for its labeled indications; renal instruction does not waive other eligibility and safety requirements.
Renal method
Qualitative renal categories, explicitly including ESRD on dialysis
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
SOTYKTU: source applicability and renal evidence limits
The RX pharmacokinetic paragraph contains a malformed lower-bound value. Only the intact explicit renal-use instruction is summarized; the numerical anomaly remains disclosed.
What to reconcile: Use the explicit renal paragraph; do not use the malformed RX PK range.
DailyMed / product prescribing information · Adult oral SOTYKTU for its labeled indications; renal instruction does not waive other eligibility and safety requirements.
Renal method: Qualitative renal categories, explicitly including ESRD on dialysis Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
No CRRT settings or modality-specific schedule supplied in the selected section.
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 8.6
No dose adjustment is recommended for mild, moderate or severe renal impairment, or ESRD on dialysis. This is an explicit renal-use instruction, not a newly derived exposure-based dose. The selected section does not specify CRRT settings. Review the full label for infection and other safety restrictions.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
